Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Jul 30;9(7):3619-3622.
doi: 10.4103/jfmpc.jfmpc_559_20. eCollection 2020 Jul.

Oral versus intravenous iron therapy in iron deficiency anemia: An observational study

Samarendra N Das  1 , Amruta Devi  2 , Bibhuti B Mohanta  3 , Anurag Choudhury  4 , Abinash Swain  4 , Pravat K Thatoi  4
Affiliations

Oral versus intravenous iron therapy in iron deficiency anemia: An observational study

Samarendra N Das et al. J Family Med Prim Care. .

Abstract

Background: Intravenous (IV) iron sucrose is claimed to have better safety profile and efficacy in treatment of iron deficiency anemia than conventional oral iron supplements.

Aim: The aim of the study was to compare the efficacy and safety of IV iron therapy with oral iron supplements in iron deficiency anemia.

Methods: An observational study was carried out by allocating 100 patients with baseline hemoglobin between 5 and 10 g/dL into two groups of oral iron and IV iron group. Hemoglobin and serum ferritin levels were measured at admission, on day 14 and on day 28. Adverse effect profile for each group was tabulated. Mean and standard deviation were calculated for each group and compared.

Results: A total of 100 patients participated consisting of 37 males and 63 females. Baseline hemoglobin and serum ferritin for both groups were comparable. After initiation of therapy, hemoglobin in oral iron group raised from 6.45 (0.72) to 8.84 (0.47) on day 14 and to 9.69 (0.47) on day 28. Hemoglobin in IV iron group increased from 6.34 (0.86) to 10.52 (0.61) on day 14 and to 11.66 (0.84) on day 28. Serum ferritin in oral iron group increased from 8.3 (1.9) to 33.8 (1.29) on day 14 and to 43.61 (8.8) on day 28. Serum ferritin in IV iron group raised from 8.23 (4.64) to 148.23 (11.86) on day 14 but decreased to 115.76 (15.3) on day 28. The data were statistically significant for IV iron therapy on day 14 and day 28. Of 100 patients, 18 patients (12 in oral and 6 in IV iron groups) had adverse effects. Among the oral iron group, metallic taste and constipation were major side effects followed by heart burn and nausea. In the IV iron group, arthralgia (4 patients of 6) was the major side effect observed. One patient (of 6) in IV group had hypotension. Anaphylaxis was not observed in any patient in either group.

Conclusion: IV iron therapy is effective and safe for management of iron deficiency anemia.

Keywords: Iron deficiency anemia; intravenous iron sucrose; oral ferrous sulfate.

PubMed Disclaimer

Conflict of interest statement

There are no conflicts of interest.

References

    1. Farkin F, Chesterman C, Penington D, Rush B. De Gruchy's Clinical hematology in Medical Practice. Germany: 2008-Blackwell Science Ltd; Hypochromic anemia: Iron deficiency and Sideroblastic anemia.
    1. Benoist De, Cogswell M, Egli I, McLean E. Worldwide Prevalence of Anaemia 1993-2005. WHO Global Database of Anaemia - PubMed
    1. Gulmezoglu AM, Vilar J, Ngoc NT, Piaggio G, Adetoro L, Abdel-Aleem H, et al. WHO multicentre randomised trial of misoprostol in the management of the third stage of labour. Lancet. 2001;358:689–95. - PubMed
    1. Cooke M, Lamplugh A, Naudeer S, Edey M, Bhandari S. Efficacy and tolerability of accelerated-dose low-molecular-weight iron dextran (cosmofer) in patients with chronic kidney disease. Am J Nephrol. 2012;35:69–74. - PubMed
    1. Agarwal KN, Agarwal DK, Sharma A, Sharma K, Prasad K, Kalita MC, et al. Prevalence of anaemia in pregnant and lactating women in India. Indian J Med Res. 2006;124:173–84. - PubMed